Login to Your Account



FDA seeks post-start design change in Concert's CF drug trial

By Michael Fitzhugh
Staff Writer

Tuesday, January 17, 2017

Concert Pharmaceuticals Inc. said in order to support dose selection for a future phase III trial of CTP-656 in CF, the FDA will require its ongoing phase II trial to institute a washout period during which Kalydeco treatment would be withheld.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription